

MarÃa JosÃ Serrano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7323583/publications.pdf>

Version: 2024-02-01

42
papers

1,254
citations

471509

17
h-index

361022

35
g-index

43
all docs

43
docs citations

43
times ranked

2228
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective. <i>Molecular Genetics and Genomics</i> , 2022, , 1.	2.1	1
2	Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103311.	4.4	24
3	Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. <i>Journal of Molecular Pathology</i> , 2021, 2, 255-273.	1.2	18
4	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	3.1	20
5	Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream). <i>Cancers</i> , 2021, 13, 6386.	3.7	10
6	Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. <i>Cancers</i> , 2021, 13, 6153.	3.7	13
7	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	9.4	52
8	International liquid biopsy standardization alliance white paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103112.	4.4	66
9	The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers. <i>Cancers</i> , 2020, 12, 3343.	3.7	11
10	Strategies for Isolation and Phenotypic, Genetic, and Functional Characterization of Circulating Tumor Cells. <i>Cancers</i> , 2020, 12, 3257.	3.7	0
11	Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2020, 10, 3974.	3.3	83
12	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	4.4	79
13	From precision medicine to imprecision medicine through limited diagnostic ability to detect low allelic frequency mutations. <i>Translational Lung Cancer Research</i> , 2020, 9, 180-183.	2.8	1
14	mRNA expression patterns in human myocardial tissue, pericardial fluid and blood, and its contribution to the diagnosis of cause of death. <i>Forensic Science International</i> , 2019, 302, 109876.	2.2	5
15	Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1750.	3.7	29
16	Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents. <i>Cells</i> , 2019, 8, 1382.	4.1	45
17	Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019, 21, 21.	5.0	130
18	Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 31-36.	4.4	17

#	ARTICLE	IF	CITATIONS
19	Genetic markers a landscape in prostate cancer. Mutation Research - Reviews in Mutation Research, 2018, 775, 1-10.	5.5	8
20	Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial. Journal of Thoracic Disease, 2018, 10, 6388-6391.	1.4	5
21	Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. Journal of Translational Medicine, 2018, 16, 251.	4.4	21
22	Significance of EGFR Expression in Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 285-296.	1.6	7
23	Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. European Journal of Cardio-thoracic Surgery, 2017, 52, 55-62.	1.4	16
24	Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness. PLoS ONE, 2017, 12, e0185447.	2.5	11
25	Exosomes as diagnostic and predictive biomarkers in lung cancer. Journal of Thoracic Disease, 2017, 9, S1373-S1382.	1.4	90
26	Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC). Surgery, 2016, 159, 728-735.	1.9	17
27	Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection. PLoS ONE, 2016, 11, e0148659.	2.5	100
28	Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications. Current Drug Targets, 2016, 17, 693-701.	2.1	8
29	Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status. Tumor Biology, 2015, 36, 711-718.	1.8	2
30	miRNA21 as a specific marker for the detection of circulating tumor cell.. Journal of Clinical Oncology, 2015, 33, e22025-e22025.	1.6	1
31	Predictive value of circulating tumor cells positive for VEGFR expression in patients with advanced colorectal cancer undergoing treatment with FOLFOX plus bevacizumab.. Journal of Clinical Oncology, 2014, 32, e22026-e22026.	1.6	0
32	Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. Expert Review of Molecular Diagnostics, 2013, 13, 295-307.	3.1	30
33	CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. International Journal of Cancer, 2013, 133, 2398-2407.	5.1	92
34	CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. Translational Lung Cancer Research, 2013, 2, 65-71.	2.8	16
35	Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Experimental and Therapeutic Medicine, 2012, 4, 43-48.	1.8	35
36	Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Research, 2012, 14, R71.	5.0	82

#	ARTICLE	IF	CITATIONS
37	EGFR mutations in circulating tumour DNA. <i>Lancet Oncology</i> , The, 2012, 13, 971-973.	10.7	28
38	Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome. <i>Clinical and Translational Oncology</i> , 2011, 13, 204-208.	2.4	8
39	Circulating cancer cells in division in an early breast cancer patient. <i>Annals of Oncology</i> , 2011, 22, 2150-2151.	1.2	7
40	Detection of circulating tumor Cells in the context of treatment: Prognostic value in breast cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 671-675.	3.4	40
41	NK Cells Mediate Increase of Phagocytic Activity but Not of Proinflammatory Cytokine (Interleukin-6) Tj ETQq1 1 0.784314 rgBT /Over Treatment of Mice during Acute Systemic Candidiasis. <i>Vaccine Journal</i> , 2002, 9, 1282-1294.	3.1	14
42	c-K<i>ras</i> Overexpression Is Characteristic for Metastases Derived from a Methylcholanthrene-Induced Fibrosarcoma. <i>Invasion & Metastasis</i> , 1998, 18, 261-270.	0.5	7